PNTG vs. WGS, PRVA, SGRY, HTFL, CON, VCYT, ADUS, CELC, PACS, and LFST
Should you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include GeneDx (WGS), Privia Health Group (PRVA), Surgery Partners (SGRY), Heartflow (HTFL), Concentra Group Holdings Parent (CON), Veracyte (VCYT), Addus HomeCare (ADUS), Celcuity (CELC), PACS Group (PACS), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry.
The Pennant Group vs. Its Competitors
The Pennant Group (NASDAQ:PNTG) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
85.9% of The Pennant Group shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 5.4% of The Pennant Group shares are owned by insiders. Comparatively, 29.6% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, GeneDx had 2 more articles in the media than The Pennant Group. MarketBeat recorded 9 mentions for GeneDx and 7 mentions for The Pennant Group. The Pennant Group's average media sentiment score of 0.38 beat GeneDx's score of 0.13 indicating that The Pennant Group is being referred to more favorably in the media.
The Pennant Group presently has a consensus price target of $34.40, indicating a potential upside of 33.02%. GeneDx has a consensus price target of $104.13, indicating a potential downside of 11.95%. Given The Pennant Group's higher probable upside, equities research analysts plainly believe The Pennant Group is more favorable than GeneDx.
The Pennant Group has higher revenue and earnings than GeneDx. The Pennant Group is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
The Pennant Group has a net margin of 3.36% compared to GeneDx's net margin of 0.39%. GeneDx's return on equity of 16.51% beat The Pennant Group's return on equity.
The Pennant Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.
Summary
GeneDx beats The Pennant Group on 8 of the 15 factors compared between the two stocks.
Get The Pennant Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Pennant Group Competitors List
Related Companies and Tools
This page (NASDAQ:PNTG) was last updated on 10/6/2025 by MarketBeat.com Staff
